Riboflavin Based Aerosol and Use as Placebo in Trials
A method for evaluating an aerosolized test compound includes administering a test compound to a first population of individuals, via inhalation of an aerosol; administering a placebo comprising riboflavin 5′-phosphate to a second population of individuals, via inhalation of an aerosol; and comparing a biological marker for the individuals in the two populations. An aerosol comprising riboflavin 5′-phosphate (also known as flavin mononucleotide) may be used either as a placebo in clinical trials, or therapeutically.
1 . A method for evaluating a test compound comprising:
administering to a first population of individuals a test compound via inhalation of an aerosol; administering to a second population of individuals a placebo comprising riboflavin 5′-phosphate via inhalation of an aerosol; and
comparing a biological marker in at least one individual administered the test compound to a biological marker in at least one individual administered the placebo.
2 . The method of claim 1 , wherein the administering the test compound comprises delivering an aerosolized solution of the test compound.
3 . The method of claim 1 , wherein the administering is intrapulmonary or intranasal.
4 . The method of claim 1 , wherein the test compound or placebo are delivered with a pulmonary delivery device.
5 . The method of claim 1 , wherein the biological marker is selected from the group consisting of a marker associated with a therapeutic effect, a marker associated with an adverse effect, a marker associated with a toxic effect, a marker associated with a pharmacodynamic parameter.
6 . The method of claim 1 , wherein the test compound comprises at least one member of the group consisting of antibiotics, antiallergics, anticancer agents, antifungals, antineoplastic agents, analgesics, bronchodilators, antihistamines, antiviral agents, antitussives, anginal preparations, anti-inflammatories, immunomodulators, 5-lipoxygenase inhibitors, leukotriene antagonists, phospholipase A2 inhibitors, phosphodiesterase IV inhibitors, peptides, proteins, steroids, and vaccine preparations.
7 . The method of claim 1 , wherein the placebo comprises a solution of riboflavin 5′-phosphate.
8 . The method of claim 7 , wherein the solution of riboflavin 5′-phosphate comprises a concentration greater than about 0.1 mg/ml.
9 . The method of claim 7 , wherein the solution of riboflavin 5′-phosphate comprises a concentration greater than about 0.06 mg/L.
10 . The method of claim 1 , wherein the riboflavin 5′-phosphate aerosol comprises a dose greater than about 0.01 mg/kg/day.
11 . The method of claim 1 , wherein the riboflavin 5′-phosphate aerosol comprises a dose greater than about 2.0 mg/kg/day.
12 . The method of claim 1 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 0.5 μm to about 4.5 μm with a geometric standard deviation less than or equal to 3.0 μm.
13 . The method of claim 1 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 1.0 μm to about 3.5 μm with a geometric standard deviation less than or equal to 2.7 μm.
14 . The method of claim 1 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 1.1 μm to about 3.1 μm with a geometric standard deviation less than or equal to 2.4 μm.
15 . The method of claim 1 , wherein the individuals are animals.
16 . A method for evaluating a test compound comprising: conducting a drug trial of a test compound and a placebo in a population of individuals, wherein the placebo comprises aerosolized riboflavin 5′-phosphate.
17 . An aerosol comprising riboflavin 5′-phosphate.
18 . The aerosol of claim 17 comprising a solution of riboflavin 5′-phosphate.
19 . The aerosol of claim 18 , wherein the solution of riboflavin 5′-phosphate comprises a concentration greater than about 0.1 mg/ml.
20 . The aerosol of claim 18 , wherein the solution of riboflavin 5′-phosphate comprises a concentration greater than about 0.06 mg/L.
21 . The aerosol of claim 17 , wherein the aerosol comprises a dose of riboflavin 5′-phosphate greater than about 0.01 mg/kg/day.
22 . The aerosol of claim 17 , wherein the aerosol comprises a dose of riboflavin 5′-phosphate greater than about 2.0 mg/kg/day.
23 . The aerosol of claim 17 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 0.5 μm to about 4.5 μm with a geometric standard deviation less than or equal to 3.0 μm.
24 . The aerosol of claim 17 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 1.0 μm to about 3.5 μm with a geometric standard deviation less than or equal to 2.7 μm.
25 . The aerosol of claim 17 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 1.1 μm to about 3.1 μm with a geometric standard deviation less than or equal to 2.4 μm.
26 . The aerosol of claim 18 , wherein the aerosol comprises a dose of riboflavin 5′-phosphate greater than about 0.01 mg/kg/day.
27 . The aerosol of claim 18 , wherein the aerosol comprises a dose of riboflavin 5′-phosphate greater than about 2.0 mg/kg/day.
28 . The aerosol of claim 18 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 0.5 μm to about 4.5 μm with a geometric standard deviation less than or equal to 3.0 μm.
29 . The aerosol of claim 18 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 1.0 μm to about 3.5 μm with a geometric standard deviation less than or equal to 2.7 μm.
30 . The aerosol of claim 18 , wherein the aerosolized riboflavin 5′-phosphate comprises a mass median aerodynamic diameter from about 1.1 μm to about 3.1 μm with a geometric standard deviation less than or equal to 2.4 μm.